Prolonged survival with continuous infusion topotecan: a report of 2 cases.
Two patients with solid tumors were treated with 21-day continuous infusion topotecan as palliation therapy. Case 1: A 10-year-old girl was diagnosed with progressive, metastatic hepatocellular carcinoma. Twenty-one-day continuous infusion topotecan was started and she has had a partial response. Case 2: A 17-year-old girl developed a malignant fibrous histiocytoma as a second malignant neoplasm. After partial resection and failure of multiagent chemotherapy, she started continuous infusion topotecan and was disease-free for 58 months when she died of pneumonia. These cases suggest that topotecan given as 21-day continuous infusion is efficacious for palliation care.
Klopfenstein
Kathryn J
KJ
Department of Pediatrics, East Tennesse State University, Johnson City, TN 37601, USA. klopfens@etsu.edu
Scott
Suzanne
S
Schuller
David E
DE
Ruymann
Frederick B
FB
D000293:Adolescent; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality; D051677:Histiocytoma, Malignant Fibrous / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007262:Infusions, Intravenous; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality; D016609:Neoplasms, Second Primary / Q000188:drug therapy / Q000401:mortality; D010166:Palliative Care; D013534:Survival; D019772:Topotecan / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D019772:Topotecan